Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.

By J. Shifren, Glenn D. Braunstein, J. A. Simon, Peter R. Casson, J. Buster, Geoffrey P. Redmond, R. E. Burki, Elizabeth S. Ginsburg, R. C. Rosen, S. Leiblum and 4 more. New England Journal of Medicine, 2000

939 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/d2d6bc2ba67ea3e61446dc9684da1e618169d07e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Psychiatry and Mental health

1. Roy F. Baumeister
2. Kathleen D. Vohs
3. Kristen P. Mark

Citations in the corpus

• ESHRE Guideline: management of women with premature ovarian insufficiency. (2016, background): “Womenshouldbe informed that androgen treatment isonlysupported by limited data, and that long-term health effects are not clear yet (Shifren et al., 2000; Braunstein et al., 2005; Buster et al., 2005; Simon et al., 2005; Davis et al., 2006, 2008; Tamimi et al., 2006; Panay et al., 2010) C”
• Is There a Gender Difference in Strength of Sex Drive? Theoretical Views, Conceptual Distinctions, and a Review of Relevant Evidence (2001, background): “265 BAUMEISTER, CATANESE, & VOHS In a recent study, researchers found that high doses of testosterone given to oophorectomized women via a skin patch (i.e., transdermally) improved sexual functioning and sexual motivation relative to receiving a placebo (Shifren et al., 2000).”